- Chemicals for Life Science -

DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.

Home > PROTACs > PROTAC

WDR5 PROTAC MS40

Cat. No.: DC74522 Featured

Chemical Structure

2407449-49-2

For research use only. We do not sell to patients.

We match the best price and quality on market.
Email:order@dcchemicals.com sales@dcchemicals.com
Tel:+86-021-58447131

Get Quotation Now

We are official vendor of:

More than 5000 active chemicals with high quality for research!

Field of application

MS40 is a cereblon (CRBN)-based proteolysis targeting chimera (PROTAC) degrader of the onco-target WD repeat domain 5 (WDR5) [1]. WDR5 is an integral component of the MLL/KMT2A lysine methyltransferase protein complex. The WDR5-binding component of MS40 is the selective inhibitor OICR-9429, and the CRBN-targeting moiety is the immunomodulatory drug pomalidomide. MS40 promotes degradation of WDR5 and the pomalidomide transcription factor neo-substrates IKZF1 and IKZF3.

Chemicals Properties Biological activity COA & MSDS Related products Datasheet

Cas No.:	2407449-49-2
Chemical Name:	WDR5 PROTAC MS40
Formula:	C₅₂H₆₁F₃N₁₀O₇
M.Wt:	995.118
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC74522	WDR5 PROTAC MS40	MS40 is a cereblon (CRBN)-based proteolysis targeting chimera (PROTAC) degrader of the onco-target WD repeat domain 5 (WDR5) [1]. WDR5 is an integral component of the MLL/KMT2A lysine methyltransferase protein complex. The WDR5-binding component of MS40 is the selective inhibitor OICR-9429, and the CRBN-targeting moiety is the immunomodulatory drug pomalidomide. MS40 promotes degradation of WDR5 and the pomalidomide transcription factor neo-substrates IKZF1 and IKZF3.

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.